New 99mTc-cytectrine piperidine compound as a specific brain imaging agent

Radiopharmaceuticals that bind to CNS receptors in vivo are useful for understanding the pathophysiology of several neuropsychiatric disorders. For the diagnosis of these pathophysiological processes it is important to develop radioligands capable of binding specifically to well-defined CNS receptors in order to evaluate their density and distribution in the brain. Owing to the availability, low cost and optimal radiation properties of 99mTc, there is a considerable interest in the development of 99mTc radiopharmaceuticals for imaging CNS receptors using single photon emission tomography